MANKIND PHARMA LTD reported a 30% rise in fourth-quarter profit to 5.54 billion rupees ($57.39 million) on Tuesday, up from 4.25 billion rupees a year earlier. The company saw revenue climb 12% to 34.43 billion rupees for the quarter ended March 31. Strong domestic demand for chronic treatments allows Mankind to outperform peers struggling with pricing pressure in the United States.

Domestic Formulations Outpace Market Growth